Cargando…

Piperazine-substituted derivatives of favipiravir for Nipah virus inhibition: What do in silico studies unravel?

Favipiravir is found to show excellent in-vitro inhibition activity against Nipah virus. To explore the structure–property relationship of Favipiravir, in silico designing of a series of piperazine substituted Favipiravir derivatives are attempted and computational screening has been done to evaluat...

Descripción completa

Detalles Bibliográficos
Autores principales: Lipin, Raju, Dhanabalan, Anantha Krishnan, Gunasekaran, Krishnasamy, Solomon, Rajadurai Vijay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7799160/
https://www.ncbi.nlm.nih.gov/pubmed/33458565
http://dx.doi.org/10.1007/s42452-020-04051-9
_version_ 1783635105587134464
author Lipin, Raju
Dhanabalan, Anantha Krishnan
Gunasekaran, Krishnasamy
Solomon, Rajadurai Vijay
author_facet Lipin, Raju
Dhanabalan, Anantha Krishnan
Gunasekaran, Krishnasamy
Solomon, Rajadurai Vijay
author_sort Lipin, Raju
collection PubMed
description Favipiravir is found to show excellent in-vitro inhibition activity against Nipah virus. To explore the structure–property relationship of Favipiravir, in silico designing of a series of piperazine substituted Favipiravir derivatives are attempted and computational screening has been done to evaluate its bimolecular interactions with Nipah virus. The geometrical features of all the molecules have been addressed from Density Functional Theory calculations. Chemical reactivity descriptor analysis was carried out to understand various reactivity parameters. The drug-likeness properties were estimated by a detailed ADMET study. The binding ability and the mode of binding of these derivatives into the Nipah virus are obtained from molecular docking studies. Our calculations show greater binding ability for the designed inhibitors compared to that of the experimentally reported molecule. Overall, the present work proves to offers new insights and guidelines for synthetic chemists to develop new drugs using piperazine substituted Favipiravir in the treatment of Nipah virus. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s42452-020-04051-9.
format Online
Article
Text
id pubmed-7799160
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-77991602021-01-12 Piperazine-substituted derivatives of favipiravir for Nipah virus inhibition: What do in silico studies unravel? Lipin, Raju Dhanabalan, Anantha Krishnan Gunasekaran, Krishnasamy Solomon, Rajadurai Vijay SN Appl Sci Research Article Favipiravir is found to show excellent in-vitro inhibition activity against Nipah virus. To explore the structure–property relationship of Favipiravir, in silico designing of a series of piperazine substituted Favipiravir derivatives are attempted and computational screening has been done to evaluate its bimolecular interactions with Nipah virus. The geometrical features of all the molecules have been addressed from Density Functional Theory calculations. Chemical reactivity descriptor analysis was carried out to understand various reactivity parameters. The drug-likeness properties were estimated by a detailed ADMET study. The binding ability and the mode of binding of these derivatives into the Nipah virus are obtained from molecular docking studies. Our calculations show greater binding ability for the designed inhibitors compared to that of the experimentally reported molecule. Overall, the present work proves to offers new insights and guidelines for synthetic chemists to develop new drugs using piperazine substituted Favipiravir in the treatment of Nipah virus. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s42452-020-04051-9. Springer International Publishing 2021-01-11 2021 /pmc/articles/PMC7799160/ /pubmed/33458565 http://dx.doi.org/10.1007/s42452-020-04051-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Lipin, Raju
Dhanabalan, Anantha Krishnan
Gunasekaran, Krishnasamy
Solomon, Rajadurai Vijay
Piperazine-substituted derivatives of favipiravir for Nipah virus inhibition: What do in silico studies unravel?
title Piperazine-substituted derivatives of favipiravir for Nipah virus inhibition: What do in silico studies unravel?
title_full Piperazine-substituted derivatives of favipiravir for Nipah virus inhibition: What do in silico studies unravel?
title_fullStr Piperazine-substituted derivatives of favipiravir for Nipah virus inhibition: What do in silico studies unravel?
title_full_unstemmed Piperazine-substituted derivatives of favipiravir for Nipah virus inhibition: What do in silico studies unravel?
title_short Piperazine-substituted derivatives of favipiravir for Nipah virus inhibition: What do in silico studies unravel?
title_sort piperazine-substituted derivatives of favipiravir for nipah virus inhibition: what do in silico studies unravel?
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7799160/
https://www.ncbi.nlm.nih.gov/pubmed/33458565
http://dx.doi.org/10.1007/s42452-020-04051-9
work_keys_str_mv AT lipinraju piperazinesubstitutedderivativesoffavipiravirfornipahvirusinhibitionwhatdoinsilicostudiesunravel
AT dhanabalanananthakrishnan piperazinesubstitutedderivativesoffavipiravirfornipahvirusinhibitionwhatdoinsilicostudiesunravel
AT gunasekarankrishnasamy piperazinesubstitutedderivativesoffavipiravirfornipahvirusinhibitionwhatdoinsilicostudiesunravel
AT solomonrajaduraivijay piperazinesubstitutedderivativesoffavipiravirfornipahvirusinhibitionwhatdoinsilicostudiesunravel